Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
16:13:51 EDT Mon 17 Jun 2024
Enter Symbol
or Name
USA
CA



Q:BLRX - BIOLINE RX LTD SPON ADS EACH REPR 15 ORD SHS - http://www.biolinerx.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
BLRX - Q0.10.6303·0.63280.90.6328-0.0324-4.9177.6992280.659  0.66  0.632.53  0.552815:58:02May 2815 min RT 2¢

Recent Trades - Last 10 of 228
Time ETExPriceChangeVolume
15:58:09Q0.64-0.0252100
15:58:08Q0.64-0.0252100
15:58:08Q0.64-0.0252100
15:58:07Q0.6328-0.0324500
15:58:07Q0.6328-0.0324200
15:58:07Q0.6328-0.0324910
15:58:07Q0.6328-0.0324100
15:58:07Q0.6328-0.0324100
15:58:07Q0.64-0.02521,400
15:58:07Q0.6322-0.033500

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-05-28 07:00U:BLRXNews ReleaseBioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates
2024-05-24 07:00U:BLRXNews ReleaseBioLineRx Announces Abstract on Pilot Study Data from Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC) at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting
2024-05-22 07:00U:BLRXNews ReleaseBioLineRx to Report First Quarter 2024 Results on May 28, 2024
2024-05-17 17:00U:BLRXNews ReleaseBioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification
2024-05-06 07:00U:BLRXNews ReleaseBioLineRx Announces Poster Presentation on Economic Model Data for APHEXDA(TM) (motixafortide) as part of CD34+ Hematopoietic Stem Cell Mobilization in Patients with Multiple Myeloma at ISPOR 2024
2024-04-17 07:00U:BLRXNews ReleaseBioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA(TM) (motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting
2024-04-10 07:00U:BLRXNews ReleaseBioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement
2024-04-01 09:00U:BLRXNews ReleaseBioLineRx Announces $6 Million Registered Direct Offering
2024-03-26 07:00U:BLRXNews ReleaseBioLineRx Reports 2023 Financial Results and Recent Corporate and Portfolio Updates
2024-03-20 07:00U:BLRXNews ReleaseBioLineRx to Report 2023 Annual Financial Results on March 26, 2024
2024-03-04 07:00U:BLRXNews ReleaseBioLineRx Strengthens Intellectual Property Estate with Notice of Allowance for U.S. Patent Covering Method of Manufacturing Motixafortide (BL-8040) Suitable for Large Scale Production
2024-02-28 07:00U:BLRXNews ReleaseBioLineRx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC)
2024-02-16 07:00U:BLRXNews ReleaseBioLineRx Announces Acceptance of Two Poster Presentations on APHEXDA ‚ ® (motixafortide) for CD34+ Hematopoietic Stem Cell (HSC) Mobilization in Patients with Multiple Myeloma at the 2024 Tandem Meetings of ASTCT ‚ ® and CIBMTR ‚ ®
2023-12-21 07:00U:BLRXNews ReleaseBioLineRx Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease
2023-11-20 07:00U:BLRXNews ReleaseBioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate and Portfolio Updates
2023-11-13 07:00U:BLRXNews ReleaseBioLineRx to Report Third Quarter 2023 Results on November 20, 2023
2023-10-31 09:00U:BLRXNews ReleaseBioLineRx entered Exclusive License Agreement to Motixafortide in Asia, advisored by M.S.Q. Ventures
2023-10-12 07:00U:BLRXNews ReleaseBioLineRx Announces Closing of Exclusive License Agreement to Motixafortide in Asia and Concurrent Strategic Equity Investment
2023-09-28 07:00U:BLRXNews ReleaseBioLineRx Announces Encouraging Data from Pilot Phase of Phase 2 Combination Clinical Trial with Motixafortide in First-Line Pancreatic Cancer (PDAC)